Hyperpolarized esters as metabolic markers in mr
US-2015374854-A1 · Dec 31, 2015 · US
Halogenated compounds for cancer imaging and treatment and methods for their use
US2016367707A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016367707-A1 |
| Application number | US-201615157075-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 17, 2016 |
| Priority date | Sep 9, 2013 |
| Publication date | Dec 22, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 and X 4 are are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123 I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
First claim
Opening claim text (preview).
1 . A compound having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: R 1 and R 2 are each independently_H or C 1 -C 10 alkyl, or R 1 and R 2 , together with the carbon atom to which they are bound, are taken together to form a carbocyclic or heterocyclic ring; R 3 , R 4 and R 5 are each independently H, C 1 -C 10 al…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016367707A1 cover?
- Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 and X 4 are are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123 I moiety, are provided. Uses …
- Who is the assignee on this patent?
- Univ British Columbia, British Columbia Cancer Agency Branch
- What technology area does this patent fall under?
- Primary CPC classification A61K51/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Dec 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).